CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of toll-like receptor 9

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 7, 2013, Pages 559-564

  Yan, Li ^a   Xu, Guoxiong ^a   Qiao, Tiankui ^a   Chen, Wei ^a   Yuan, Sujuan ^a   Li, Xuan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CpG ODN; lung cancer; radiosensitivity; TLR 9

Indexed keywords

AGATOLIMOD; CHOLECYSTOKININ OCTAPEPTIDE; CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ARTICLE; CARCINOMA CELL; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IRRADIATION; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; SURVIVAL RATE; WESTERN BLOTTING;

ADENOCARCINOMA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LUNG NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS;

EID: 84881432388     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1450     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69
2. Mitsuhashi N, Takahashi T, Sakurai H, et al. A radioresistant variant cell line, NMT-1R, isolated from a radiosensitive rat yolk sac tumour cell line, NMT-1: Differences of early radiation-induced morphological changes, especially apoptosis. Int J Radiat Biol 1996;69:329
3. Li YZ, Fan J, Ma HY, et al. Elevated level of polysaccharides in a high level UV-B tolerant cell line of Bupleurum scorzonerifolium Willd. Afr J Biotechnol 2011;10:5578
4. Henness S, Davey MW, Harvie RM, et al. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIa expression. Int J Radiat Oncol Biol Phys 2002;54:895
5. Xie L, Song X, Yu J, et al. Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer. J Cancer Res Clin Oncol 2011;137:1739
6. Efimova EV, Liang H, Pitroda SP, et al. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 2009;85:421
7. Mauceri HJ, Sutton HG, Darga TE, et al. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep 2012;27:1625
8. Furihata T, Ishii Y, Miyoshi M, et al. [Clinical investigation of weekly cisplatin and vinorelbine with concurrent radiation therapy for locally advanced non-small cell lung cancer]. Gan To Kagaku Ryoho 2011;38:1313
9. Zhang X, Yang H, Gu K, et al. In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer. Int J Nanomed 2011;6:437
10. Arnoletti JP, Frolov A, Eloubeidi M, et al. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2011;67:891
11. Xiong H, Lee RJ, Haura EB, et al. Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNAdependent protein kinase catalytic subunit. Int J Radiat Oncol Biol Phys 2012;83:1023
12. Yuan S, Qiao T, Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm 2011;26:203
13. Li R, Song Y, Chen W. Enhancing radiosensitivity of human pulmonary adenocarcinoma cell line A549 by CpG ODN 1826. Cancer Biother Radiopharm 2011;26:69
14. Zha L, Qiao T, Yuan S, Lei L. Enhancement of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells. Cancer Biother Radiopharm 2010;25:165
15. Wazer DE, Joyce M, Jung L, Band V. Alterations in growth phenotype and radiosensitivity after fractionated irradiation of breast carcinoma cells from a single patient. Int J Radiat Oncol Biol Phys 1993;26:81
16. Lee JU, Hosotani R, Wada M, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 1999;35: 1374
17. Du L, Zhou LJ, Pan XJ, et al. Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat Oncol 2010; 5:70
18. Brooks C, Sheu T, Bridges K, et al. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 2012;7: 154
19. Hong S, Qian J, Li H, et al. CpG or IFN-alpha are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 2012;61:561
20. Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol 2012;746:95
21. Sorrentino R, Morello S, Forte G, et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med 2011;183:1369
22. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27
23. Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996;93:2879
24. Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 1996;156:558
25. Shepherd FA, Douillard JY, Blumenschein GJ. Immunotherapy for non-small cell lung cancer: Novel approaches to improve patient outcome. J Thorac Oncol 2011;6: 1763
26. Liu J, Xu C, Liu YL, et al. Activation of rabbit TLR9 by different CpG-ODN optimized for mouse and human TLR9. Comp Immunol Microbiol Infect Dis 2012;35:443
27. Kim IY, Yan X, Tohme S, et al. CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model. J Surg Res 2012;174:284
28. Chinnathambi S, Chen S, Ganesan S, Hanagata N. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci Rep 2012;2:534
29. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol 2004;59:928.